Last reviewed · How we verify
IV ondansetron hydrochloride — Competitive Intelligence Brief
phase 3
5-HT3 receptor antagonist
5-HT3 receptor
Oncology, Gastroenterology
Small molecule
Live · refreshed every 30 min
Target snapshot
IV ondansetron hydrochloride (IV ondansetron hydrochloride) — GlaxoSmithKline. Ondansetron blocks serotonin (5-HT3) receptors on chemoreceptor trigger zone and vagal afferent nerves to prevent nausea and vomiting.
Comparator set (6 drugs)
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| IV ondansetron hydrochloride TARGET | IV ondansetron hydrochloride | GlaxoSmithKline | phase 3 | 5-HT3 receptor antagonist | 5-HT3 receptor | |
| Trintellix | vortioxetine | Takeda | marketed | Serotonin modulator and stimulator (SMS); SSRI-like agent | Serotonin transporter (SERT); 5-HT3 receptor; 5-HT1A receptor | 2013-01-01 |
| Zofran inj.+Zofran tab. | Zofran inj.+Zofran tab. | LG Life Sciences | marketed | 5-HT3 receptor antagonist | 5-HT3 receptor | |
| fosnetupitant/ palonosetron | fosnetupitant/ palonosetron | Helsinn Healthcare SA | marketed | NK1 receptor antagonist / 5-HT3 receptor antagonist combination | NK1 receptor (substance P receptor) / 5-HT3 receptor | |
| Aprepitant plus Ondansetron | Aprepitant plus Ondansetron | University of Pittsburgh | marketed | NK1 receptor antagonist + 5-HT3 receptor antagonist combination | NK1 receptor (aprepitant); 5-HT3 receptor (ondansetron) | |
| Ondansetron orodispersible film once | Ondansetron orodispersible film once | Chongqing University Cancer Hospital | marketed | 5-HT3 receptor antagonist | 5-HT3 receptor | |
| Ondansetron (ODT) | Ondansetron (ODT) | MonoSol Rx | marketed | 5-HT3 receptor antagonist | 5-HT3 receptor |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape (5-HT3 receptor antagonist class)
- Helsinn Healthcare SA · 4 drugs in this class
- LG Life Sciences · 3 drugs in this class
- University of Malaya · 2 drugs in this class
- GlaxoSmithKline · 1 drug in this class
- Hamad Medical Corporation · 1 drug in this class
- Eye & ENT Hospital of Fudan University · 1 drug in this class
- Instituto Mexicano del Seguro Social · 1 drug in this class
- Chongqing University Cancer Hospital · 1 drug in this class
- Merck Sharp & Dohme LLC · 1 drug in this class
- MonoSol Rx · 1 drug in this class
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- IV ondansetron hydrochloride CI watch — RSS
- IV ondansetron hydrochloride CI watch — Atom
- IV ondansetron hydrochloride CI watch — JSON
- IV ondansetron hydrochloride alone — RSS
- Whole 5-HT3 receptor antagonist class — RSS
Cite this brief
Drug Landscape (2026). IV ondansetron hydrochloride — Competitive Intelligence Brief. https://druglandscape.com/ci/iv-ondansetron-hydrochloride. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab